Targeted therapies for small cell lung cancer: Where do we stand?

Arcaro, Alexandre (2015). Targeted therapies for small cell lung cancer: Where do we stand? Critical reviews in oncology, hematology, 95(2), pp. 154-164. Elsevier 10.1016/j.critrevonc.2015.03.001

[img] Text
1-s2.0-S1040842815000475-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy

Small cell lung cancer (SCLC) accounts for 15% of lung cancer cases and is associated with a dismal prognosis. Standard therapeutic regimens have been improved over the past decades, but without a major impact on patient survival. The development of targeted therapies based on a better understanding of the molecular basis of the disease is urgently needed. At the genetic level, SCLC appears very heterogenous, although somatic mutations targeting classical oncogenes and tumor suppressors have been reported. SCLC also possesses somatic mutations in many other cancer genes, including transcription factors, enzymes involved in chromatin modification, receptor tyrosine kinases and their downstream signaling components. Several avenues have been explored to develop targeted therapies for SCLC. So far, however, there has been limited success with these targeted approaches in clinical trials. Further progress in the optimization of targeted therapies for SCLC will require the development of more personalized approaches for the patients.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine
04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine > Paediatric Haematology/Oncology

UniBE Contributor:

Arcaro, Alexandre

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1040-8428

Publisher:

Elsevier

Language:

English

Submitter:

André Schaller

Date Deposited:

07 Apr 2016 14:49

Last Modified:

04 Oct 2018 09:33

Publisher DOI:

10.1016/j.critrevonc.2015.03.001

PubMed ID:

25800975

Uncontrolled Keywords:

Angiogenesis; Apoptosis; Epigenetics; Immunotherapy; Receptor tyrosine kinase; Small cell lung cancer

BORIS DOI:

10.7892/boris.79248

URI:

https://boris.unibe.ch/id/eprint/79248

Actions (login required)

Edit item Edit item
Provide Feedback